Retatrutide

Retatrutide is the most potent weight-loss agent in clinical development among the incretin agonists. It remains investigational and is not approved by any regulator as of August 2026.

The mechanism is the most complex of the four molecules compared here. Retatrutide activates three hormone receptors on a single peptide: GIP, GLP-1, and glucagon. The GIP and GLP-1 components deliver the same incretin effects as tirzepatide (glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, appetite reduction). The glucagon receptor agonism adds a distinct mechanism: increased energy expenditure and hepatic fat oxidation. This triple agonism is designed to produce greater weight loss than dual or single agonists.

Phase 2 data (NCT04881760, 48 weeks) showed up to 24.2% mean weight reduction at 48 weeks. The body composition substudy (N=189, 36 weeks, DXA) measured fat mass reduction of 26.1% (8 mg pooled dose) and 23.2% (12 mg dose) versus 4.5% with placebo. The publication states the proportion of lean mass loss to total weight loss was similar to other obesity treatments, but does not disclose an exact lean-mass percentage. This makes retatrutide's muscle-sparing profile less precisely characterized than tirzepatide's.

Phase 3 results are the strongest in this comparison. TRIUMPH-1 (obesity, 80 weeks with extension to 104 weeks for BMI 35 or higher) showed 28.3% mean weight loss with 12 mg, 25.9% with 9 mg, and 19.0% with 4 mg. The BMI 35 extension subgroup reached 30.3% at 104 weeks. 45.3% of the 12 mg group achieved 30% or greater weight loss. TRIUMPH-4 (obesity with knee osteoarthritis, 68 weeks) showed 28.7% weight loss with 12 mg and 26.4% with 9 mg, with WOMAC pain score reduction of 4.4 to 4.5 points versus 2.4 points placebo. TRIUMPH-2 (type 2 diabetes with obesity, N=1,152, 80 weeks) used 4 mg, 9 mg, and 12 mg doses with escalation from 2 mg.

No completed cardiovascular outcomes trial exists. TRIUMPH-1 reported significant improvements in cardiovascular risk factors: waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein (hsCRP). These are risk-factor changes, not adjudicated cardiovascular event outcomes.

Safety data is still emerging. As a triple agonist acting through the GLP-1 receptor pathway, retatrutide is expected to share class gastrointestinal effects (nausea, vomiting, diarrhea). Thyroid C-cell tumor precautions would be expected pending final FDA labeling upon approval.

For longevity, the glucagon receptor agonism adds energy expenditure and hepatic fat oxidation mechanisms not present in semaglutide or tirzepatide. The hsCRP reduction in TRIUMPH-1 suggests anti-inflammatory effects. The WOMAC pain reduction in TRIUMPH-4 suggests joint-load reduction or anti-inflammatory effects relevant to healthspan in osteoarthritis. The 30.3% weight loss approaches bariatric surgery levels, but also carries the largest absolute lean-mass loss risk in absolute terms, even if the lean-to-fat loss ratio is comparable to other obesity therapies.